Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Xebra Brands (XBRA) has commenced formal cannabis cultivation in the Netherlands, including THC varietals
  • Xebra was one of only five companies selected by the Dutch government to participate in trial medicinal cannabis cultivation
  • The company is working towards a 6-year contract to co-supply all pharma-grade cannabis to be sold in the Netherlands
  • Xebra’s operations in the Netherlands is led by Harry von Duijne, an experienced cannabis horticulture expert with more than two decades of practicing horticulture
  • Xebra Brands is an international cannabis cultivation and product company
  • Xebra Brands Ltd. (XBRA) is up 1.72 per cent on the day, trading at C$0.295 per share at 11:45 am EST

Xebra Brands (XBRA) has commenced formal cannabis cultivation in the Netherlands, including THC varietals.

As one of only five companies selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is hoping to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to US$79 million, to co-supply all pharma-grade cannabis to be sold in the Netherlands.

Cultivation in the Netherlands is conducted in Xebra’s indoor facility. Xebra’s specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine-tasting terpene profiles, with a growth cycle of 12-16 weeks.

Xebra’s Director of Operations in the Netherlands, Harry von Duijne, is an experienced cannabis horticulture expert with more than two decades of practicing horticulture. He had a leading role at Bedrocan NL® from 2014 and 2017, where he was responsible for managing every aspect of operations of a state-of-the-art cannabis facility, from construction through cultivation and processing, quality management, and GMP certification.

Xebra Brands is an international cannabis cultivation and product company.

Xebra Brands Ltd. (XBRA) is up 1.72 per cent on the day, trading at C$0.295 per share at 11:45 am EST.

More From The Market Herald

" BioHarvest (CSE:BHSC) predicts 2022 revenue to grow up to 3.5 times

BioHarvest Sciences Inc. (BHSC) expects strong revenue growth to continue in 2022 due to a successful over-delivery of projected revenue targets from last year.

" Icanic Brands (CSE:ICAN) agrees to acquire cannabis extraction company

Icanic Brands Company (ICAN) has signed a definitive agreement to acquire 100 per cent of LEEF Holdings Inc.
Tilray - Denise Faltischek, Head of International and Chief Strategy Officer.

" Tilray (TSX:TLRY) expands Australian medical cannabis offering

Tilray (TLRY) has expanded its medical cannabis product suite in Australia.

" Craftport Cannabis (CSE:CFT) announces $3M private placement

Craftport Cannabis (CFT) has announced a non-brokered private placement for gross proceeds of $3 million.